{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:19:27Z","timestamp":1774585167293,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.pharma.2023.09.004","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T15:27:21Z","timestamp":1695223641000},"page":"420-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Greens appraisal of validated stability indicating RP-HPLC method and forced degradation study for quantification of Ebastine in wastewater and dosage form"],"prefix":"10.1016","volume":"82","author":[{"given":"Manal A.","family":"Almalki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahani Y.A.","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar M.","family":"Mahgoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma I.","family":"Abo El-Ela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2023.09.004_bib0155","doi-asserted-by":"crossref","first-page":"00202","DOI":"10.1016\/j.teac.2023.e00202","article-title":"How environmentally friendly is the analytical process? A paradigm overview of ten greenness assessment metric approaches for analytical methods","volume":"38","author":"Imam","year":"2023","journal-title":"Trends Environ Anal Chem"},{"key":"10.1016\/j.pharma.2023.09.004_bib0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pharma.2020.07.007","article-title":"Evaluation of assay and in-vitro dissolution profile of certain fixed-dose combination using green analytical method","volume":"79","author":"Lotfy","year":"2021","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.pharma.2023.09.004_bib0165","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.pharma.2020.04.006","article-title":"and stability-indicating RP-HPLC for the assay of dextromethorphan hydrobromide and menthol in their lozenges","volume":"78","author":"Ragab","year":"2020","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.pharma.2023.09.004_bib0170","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/chromsci\/bmab070","article-title":"DoE-based analytical quality risk management for enhanced AQbD approach to economical and eco-friendly RP-HPLC method for synchronous estimation of multiple FDC products of antihypertensive drugs","volume":"60","author":"Prajapati","year":"2022","journal-title":"J Chromatogr Sci"},{"key":"10.1016\/j.pharma.2023.09.004_bib0175","unstructured":"British Pharmacopoeia Stationery Office, Medicines and Healthcare Products Regulatory Agency. 2023; London, Vol. II."},{"key":"10.1016\/j.pharma.2023.09.004_bib0180","first-page":"93","article-title":"Comparative antiallergic effects of second-generation H1-antihistamines ebastine, cetirizine and loratadine in preclinical models","volume":"53","author":"Llupi\u00e0","year":"2003","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharma.2023.09.004_bib0185","first-page":"1193","article-title":"Sedation and antihistaminics","volume":"32","author":"Weiner","year":"1982","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharma.2023.09.004_bib0190","first-page":"22","article-title":"A cost of illness study of allergic rhinitis in the United States","volume":"99","author":"Malone","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharma.2023.09.004_bib0195","first-page":"1","article-title":"Management of allergic rhinitis in the working-age population","volume":"67","author":"McCrory","year":"2003","journal-title":"Evid Rep Technol Assess (Summ)"},{"key":"10.1016\/j.pharma.2023.09.004_bib0200","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1034\/j.1398-9995.1999.00984.x","article-title":"A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis","volume":"54","author":"Bousquet","year":"1999","journal-title":"Allergy"},{"key":"10.1016\/j.pharma.2023.09.004_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1398-9995.2008.01897.x","article-title":"Ebastine in allergic rhinitis and chronic idiopathic urticaria","volume":"63","author":"Sastre","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.pharma.2023.09.004_bib0210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1081-1206(10)63269-3","article-title":"Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults","volume":"76","author":"Gehanno","year":"1996","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.pharma.2023.09.004_bib0215","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000088869","article-title":"Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis","volume":"138","author":"Ratner","year":"2005","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.pharma.2023.09.004_bib0220","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00044011-200727070-00002","article-title":"A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction to histamine in healthy adults","volume":"27","author":"Antonijoan","year":"2007","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pharma.2023.09.004_bib0225","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00003495-199600521-00008","article-title":"Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults","volume":"52","author":"Kalis","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.pharma.2023.09.004_bib0230","first-page":"56","article-title":"A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis","volume":"14","author":"Hampel","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.pharma.2023.09.004_bib0235","first-page":"82","article-title":"Ebastine vs. terfenadine in allergic rhinitis","volume":"40","author":"Ort\u00edz","year":"1993","journal-title":"Rev Alerg"},{"key":"10.1016\/j.pharma.2023.09.004_bib0240","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1472-8206.2000.tb00423.x","article-title":"Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers","volume":"14","author":"Frossard","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pharma.2023.09.004_bib0245","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1185\/03007999509110490","article-title":"Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis","volume":"13","author":"Conde Hernandez","year":"1995","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharma.2023.09.004_bib0250","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00003495-200565030-00004","article-title":"Second-generation antihistamines: actions and efficacy in the management of allergic disorders","volume":"65","author":"Golightly","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.pharma.2023.09.004_bib0255","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11356-009-0144-2","article-title":"The occurrence of antihistamines in sewage waters and in recipient rivers","volume":"16","author":"Kosonen","year":"2009","journal-title":"Environ Sci Pollut Res Int"},{"key":"10.1016\/j.pharma.2023.09.004_bib0260","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4103\/0250-474X.43022","article-title":"Determination of ebastine in pharmaceutical formulations by HPLC","volume":"70","author":"Prabu","year":"2008","journal-title":"Indian J Pharm Sci"},{"key":"10.1016\/j.pharma.2023.09.004_bib0265","first-page":"9372","article-title":"Stability indicating hplc method for antihistamine drug elastin along with degradation kinetic study","volume":"7","author":"Patel","year":"2018","journal-title":"Int J Curr Adv Res"},{"key":"10.1016\/j.pharma.2023.09.004_bib0270","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1752-153X-5-24","article-title":"Validated stability indicating liquid chromatographic determination of ebastine in pharmaceuticals after pre column derivatization: application to tablets and content uniformity testing","volume":"5","author":"Ibrahim","year":"2011","journal-title":"Chem Cent J"},{"key":"10.1016\/j.pharma.2023.09.004_bib0275","doi-asserted-by":"crossref","first-page":"8","DOI":"10.22456\/2527-2616.128122","article-title":"Stability-indicating RP-HPLC method applied to the quantification of anti-histaminic drug ebastine in its oral suspension dosage form","volume":"6","author":"Koduru","year":"2023","journal-title":"Drug Anal Res"},{"key":"10.1016\/j.pharma.2023.09.004_bib0280","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pharma.2022.09.001","article-title":"Validated stability indicating chromatographic method for determination of baricitinib and its degradation products in their tablet dosage form: implementation to content uniformity and in vitro dissolution studies","volume":"81","author":"Mohamed","year":"2023","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.pharma.2023.09.004_bib0285","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1039\/c0gc00524j","article-title":"Analytical Method Volume Intensity (AMVI): a green chemistry metric for HPLC methodology in the pharmaceutical industry","volume":"13","author":"Hartman","year":"2011","journal-title":"Green Chem"},{"key":"10.1016\/j.pharma.2023.09.004_bib0290","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","article-title":"Analytical Eco-Scale for assessing the greenness of analytical procedures, TrAC","volume":"37","author":"Ga\u0142uszka","year":"2012","journal-title":"Trends Anal Chem"},{"key":"10.1016\/j.pharma.2023.09.004_bib0295","first-page":"1165","article-title":"AGREEprep-Analytical greenness metric for sample preparation","volume":"149","author":"Wojnowski","year":"2022","journal-title":"TrAC"},{"key":"10.1016\/j.pharma.2023.09.004_bib0300","first-page":"05","article-title":"Validation of analytical procedures: text and methodology","volume":"1","author":"Guideline","year":"2005","journal-title":"Q2 (R1)"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450923001074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450923001074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T20:11:22Z","timestamp":1713298282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450923001074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0003450923001074"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2023.09.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Greens appraisal of validated stability indicating RP-HPLC method and forced degradation study for quantification of Ebastine in wastewater and dosage form","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2023.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}